OUTLOOK End Period Cash Flow from 2010 to 2024

OTLK Stock  USD 2.01  0.31  18.24%   
OUTLOOK THERAPEUTICS End Period Cash Flow yearly trend continues to be quite stable with very little volatility. End Period Cash Flow may rise above about 15.7 T this year. From the period between 2010 and 2024, OUTLOOK THERAPEUTICS, End Period Cash Flow regression line of its data series had standard deviation of  5,385,646,643,469 and standard deviation of  5,385,646,643,469. View All Fundamentals
 
End Period Cash Flow  
First Reported
2014-09-30
Previous Quarter
47.2 M
Current Value
32 M
Quarterly Volatility
17.9 M
 
Yuan Drop
 
Covid
Check OUTLOOK THERAPEUTICS financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OUTLOOK THERAPEUTICS's main balance sheet or income statement drivers, such as Depreciation And Amortization of 37.8 K, Interest Expense of 3.3 T or Selling General Administrative of 31.4 T, as well as many indicators such as Price To Sales Ratio of 2.84, Dividend Yield of 12.5 K or Days Sales Outstanding of 190. OUTLOOK financial statements analysis is a perfect complement when working with OUTLOOK THERAPEUTICS Valuation or Volatility modules.
  
Check out the analysis of OUTLOOK THERAPEUTICS Correlation against competitors.

Latest OUTLOOK THERAPEUTICS's End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of OUTLOOK THERAPEUTICS INC over the last few years. It is OUTLOOK THERAPEUTICS's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OUTLOOK THERAPEUTICS's overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

OUTLOOK End Period Cash Flow Regression Statistics

Arithmetic Mean2,040,103,629,377
Geometric Mean37,974,405
Coefficient Of Variation263.99
Mean Deviation3,536,166,085,499
Median8,015,528
Standard Deviation5,385,646,643,469
Sample Variance29005189768309.1T
Range15.7T
R-Value0.59
Mean Square Error20326018158359.3T
R-Squared0.35
Significance0.02
Slope711,724,316,355
Total Sum of Squares406072656756327.7T

OUTLOOK End Period Cash Flow History

202415.7 T
202314.9 T
202223.4 M
202117.4 M
202014.5 M
201912.5 M
2018M

About OUTLOOK THERAPEUTICS Financial Statements

OUTLOOK THERAPEUTICS investors utilize fundamental indicators, such as End Period Cash Flow, to predict how OUTLOOK Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
End Period Cash Flow14.9 T15.7 T

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether OUTLOOK THERAPEUTICS INC is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if OUTLOOK Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Outlook Therapeutics Inc Stock. Highlighted below are key reports to facilitate an investment decision about Outlook Therapeutics Inc Stock:
Check out the analysis of OUTLOOK THERAPEUTICS Correlation against competitors.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OUTLOOK THERAPEUTICS. If investors know OUTLOOK will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OUTLOOK THERAPEUTICS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.06)
Revenue Per Share
0.119
Quarterly Revenue Growth
6.583
Return On Assets
(0.84)
Return On Equity
(0.04)
The market value of OUTLOOK THERAPEUTICS INC is measured differently than its book value, which is the value of OUTLOOK that is recorded on the company's balance sheet. Investors also form their own opinion of OUTLOOK THERAPEUTICS's value that differs from its market value or its book value, called intrinsic value, which is OUTLOOK THERAPEUTICS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OUTLOOK THERAPEUTICS's market value can be influenced by many factors that don't directly affect OUTLOOK THERAPEUTICS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OUTLOOK THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if OUTLOOK THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OUTLOOK THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.